Basic information Safety Supplier Related

Naquotinib (mesylate)

Basic information Safety Supplier Related

Naquotinib (mesylate) Basic information

Product Name:
Naquotinib (mesylate)
Synonyms:
  • Naquotinib (mesylate)
  • Naquotinib mesylate (ASP8273 mesylate)
  • ASP8273 (mesylate)
  • EGFR,ASP8273,ErbB-1,ASP 8273,Inhibitor,Naquotinib mesylate,ASP-8273,HER1,Epidermal growth factor receptor,inhibit,Naquotinib
  • Naquotinib mesylate (ASP-8273)
CAS:
1448237-05-5
MF:
C31H46N8O6S
MW:
658.81194
Mol File:
1448237-05-5.mol
More
Less

Naquotinib (mesylate) Chemical Properties

storage temp. 
Store at -20°C
solubility 
DMSO : 12.5 mg/mL (18.97 mM)
form 
Solid
color 
Light yellow to yellow
More
Less

Naquotinib (mesylate) Usage And Synthesis

Uses

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

in vivo

Oral Naquotinib treatment dose dependently induces tumor regression in NCI-H1975 (L858R/T790M), HCC827 (del ex19) and PC-9 (del ex19) xenograft models. Dosing schedules does not affect the efficacy of Naquotinib. In an NCI-H1975 xenograft model, complete regression of tumor is achieved after 14-days of Naquotinib treatment. Complete regression is maintained in 50% of mice more than 85 days after cessation of Naquotinib treatment[2].

IC 50

EGFRL858R/T790M; EGFRL858R; EGFRExon 19 deletion; EGFRExon 19 deletion/T790M; EGFR: 230 nM (IC50)

References

[1] Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445.AM2014-1728
[2] Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2586. doi:10.1158/1538-7445.AM2015-2586

Naquotinib (mesylate)Supplier

MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Shanghai XingMo Biotechnology Co., Ltd.
Tel
+86 13524779951; 13524779951
Email
2075692521@qq.com
Amadis Chemical Company Limited
Tel
571-89925085
Email
sales@amadischem.com
Musechem
Tel
+1-800-259-7612
Email
info@musechem.com